{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:18:58Z","timestamp":1783678738009,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11523-022-00891-0","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T14:34:04Z","timestamp":1655130844000},"page":"329-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8958-7909","authenticated-orcid":false,"given":"Laura C.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-2602","authenticated-orcid":false,"given":"Sydney","family":"Kuehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo B.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"U\u2019Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7237-017X","authenticated-orcid":false,"given":"Laura Q. M.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Kaldjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayakrishna K.","family":"Gadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"17","key":"891_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"11","key":"891_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"891_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.","journal-title":"J Immunother Cancer"},{"issue":"22","key":"891_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.21037\/atm.2019.10.24","volume":"7","author":"M Eckstein","year":"2019","unstructured":"Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, et al. PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med. 2019;7(22):690.","journal-title":"Ann Transl Med."},{"issue":"1","key":"891_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13058-020-01303-9","volume":"22","author":"H Guo","year":"2020","unstructured":"Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, et al. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res. 2020;22(1):69.","journal-title":"Breast Cancer Res"},{"issue":"21","key":"891_CR6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"891_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, Carpeno JdC, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723\u201333.","journal-title":"J Clin Oncol"},{"issue":"8","key":"891_CR8","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.celrep.2017.07.075","volume":"20","author":"M Gato-Ca\u00f1as","year":"2017","unstructured":"Gato-Ca\u00f1as M, Zuazo M, Arasanz H, Iba\u00f1ez-Vea M, Lorenzo L, Fernandez-Hinojal G, et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. 2017;20(8):1818\u201329.","journal-title":"Cell Rep"},{"issue":"1","key":"891_CR9","first-page":"1","volume":"10","author":"X Ju","year":"2020","unstructured":"Ju X, Zhang H, Zhou Z, Wang Q. Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. Am J Cancer Res. 2020;10(1):1\u201311.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"891_CR10","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00262-020-02586-9","volume":"69","author":"Y Yan","year":"2020","unstructured":"Yan Y, Zheng L, Du Q, Yan B, Geller DA. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol Immunother. 2020;69(9):1891\u2013903.","journal-title":"Cancer Immunol Immunother"},{"key":"891_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40425-017-0229-2","volume":"5","author":"JW Smithy","year":"2017","unstructured":"Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, et al. Nuclear IRF-1 expression as a mechanism to assess \u201cCapability\u201d to express PD-L1 and response to PD-1 therapy in metastatic melanoma. J Immunother Cancer. 2017;5:25.","journal-title":"J Immunother Cancer"},{"issue":"37","key":"891_CR12","doi-asserted-by":"publisher","first-page":"60975","DOI":"10.18632\/oncotarget.17689","volume":"8","author":"T Shen","year":"2017","unstructured":"Shen T, Chen Z, Zhao ZJ, Wu J. Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the. Oncotarget. 2017;8(37):60975\u201386.","journal-title":"Oncotarget"},{"issue":"10","key":"891_CR13","first-page":"5713","volume":"37","author":"N Haratake","year":"2017","unstructured":"Haratake N, Toyokawa G, Tagawa T, Kozuma Y, Matsubara T, Takamori S, et al. Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab. Anticancer Res. 2017;37(10):5713\u20137.","journal-title":"Anticancer Res"},{"issue":"6","key":"891_CR14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41416-019-0541-3","volume":"121","author":"K Yoneda","year":"2019","unstructured":"Yoneda K, Kuwata T, Kanayama M, Mori M, Kawanami T, Yatera K, et al. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer. 2019;121(6):490\u20136.","journal-title":"Br J Cancer"},{"issue":"10","key":"891_CR15","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.3390\/ijms20102578","volume":"20","author":"T Takahashi","year":"2019","unstructured":"Takahashi T, Tateishi A, Bychkov A, Fukuoka J. Remarkable alteration of PD-L1 Expression after immune checkpoint therapy in patients with non-small-cell lung cancer: two autopsy case reports. Int J Mol Sci. 2019;20(10):2578.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"891_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001558","volume":"8","author":"M Rozenblit","year":"2020","unstructured":"Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, et al. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer. 2020;8(2): e001558.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"891_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s12967-020-02636-x","volume":"18","author":"XL Wei","year":"2020","unstructured":"Wei XL, Luo X, Sheng H, Wang Y, Chen DL, Li JN, et al. PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer. J Transl Med. 2020;18(1):475.","journal-title":"J Transl Med"},{"issue":"4","key":"891_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.eururo.2018.06.028","volume":"74","author":"M Eckstein","year":"2018","unstructured":"Eckstein M, Sikic D, Strissel PL, Erlmeier F, Germany BC. Evolution of PD-1 and PD-L1 gene and protein expression in primary tumors and corresponding liver metastases of metastatic bladder cancer. Eur Urol. 2018;74(4):527\u20139.","journal-title":"Eur Urol"},{"issue":"15_suppl","key":"891_CR19","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1200\/JCO.2017.35.15_suppl.4537","volume":"35","author":"W Arafat","year":"2017","unstructured":"Arafat W, Stahlfeld C, Sperger JM, Heninger E, Gopalakrishnan D, Barata PC, et al. Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: a pilot study. J Clin Oncol. 2017;35(15_suppl):4537.","journal-title":"J Clin Oncol"},{"issue":"1","key":"891_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41598-018-36096-7","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang Y, Kim TH, Fouladdel S, Zhang Z, Soni P, Qin A, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer. Sci Rep. 2019;9(1):566.","journal-title":"Sci Rep"},{"key":"891_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12885-015-1383-x","volume":"15","author":"DE Campton","year":"2015","unstructured":"Campton DE, Ramirez AB, Nordberg JJ, Drovetto N, Clein AC, Varshavskaya P, et al. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer. 2015;15:360.","journal-title":"BMC Cancer"},{"issue":"12","key":"891_CR22","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/cyto.a.23619","volume":"93","author":"EP Kaldjian","year":"2018","unstructured":"Kaldjian EP, Ramirez AB, Sun Y, Campton DE, Werbin JL, Varshavskaya P, et al. The RareCyte\u00ae platform for next-generation analysis of circulating tumor cells. Cytometry A. 2018;93(12):1220\u20135.","journal-title":"Cytometry A"},{"issue":"44","key":"891_CR23","doi-asserted-by":"publisher","first-page":"27460","DOI":"10.18632\/oncotarget.25446","volume":"9","author":"V Rolfes","year":"2018","unstructured":"Rolfes V, Idel C, Pries R, Pl\u00f6tze-Martin K, Habermann J, Gemoll T, et al. PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget. 2018;9(44):27460\u201370.","journal-title":"Oncotarget"},{"issue":"2","key":"891_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"891_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"key":"891_CR26","unstructured":"Meyers JaM, JN, editor Cutpoint Determination Methods in Survival Analysis using SAS: UPdated%FINDCUT macro. 28th SAS Users Group International Conference (SUGI); 2003."},{"issue":"1","key":"891_CR27","doi-asserted-by":"publisher","first-page":"11373","DOI":"10.1038\/s41598-017-11949-9","volume":"7","author":"D Fujimoto","year":"2017","unstructured":"Fujimoto D, Uehara K, Sato Y, Sakanoue I, Ito M, Teraoka S, et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep. 2017;7(1):11373.","journal-title":"Sci Rep"},{"issue":"8","key":"891_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3390\/cells8080809","volume":"8","author":"V Kloten","year":"2019","unstructured":"Kloten V, Lampignano R, Krahn T, Schlange T. Circulating tumor cell PD-L1 expression as biomarker for therapeutic efficacy of immune checkpoint inhibition in NSCLC. Cells. 2019;8(8):809.","journal-title":"Cells"},{"key":"891_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06585-5","author":"L Dirix","year":"2022","unstructured":"Dirix L, Buys A, Oeyen S, Peeters D, Li\u00e8geois V, Prov\u00e9 A, et al. Circulating tumor cell detection: a prospective comparison between Cell Search\u00ae and RareCyte\u00ae platforms in patients with progressive metastatic breast cancer. Breast Cancer Res Treat. 2022. https:\/\/doi.org\/10.1007\/s10549-022-06585-5.","journal-title":"Breast Cancer Res Treat"},{"key":"891_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2018.04.001","volume":"120","author":"N Guibert","year":"2018","unstructured":"Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer. 2018;120:108\u201312.","journal-title":"Lung Cancer"},{"key":"891_CR31","doi-asserted-by":"publisher","first-page":"31726","DOI":"10.1038\/srep31726","volume":"6","author":"C Nicolazzo","year":"2016","unstructured":"Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep. 2016;6:31726.","journal-title":"Sci Rep"},{"issue":"1","key":"891_CR32","doi-asserted-by":"publisher","first-page":"1738798","DOI":"10.1080\/2162402X.2020.1738798","volume":"9","author":"S Bergmann","year":"2020","unstructured":"Bergmann S, Coym A, Ott L, Soave A, Rink M, Janning M, et al. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). Oncoimmunology. 2020;9(1):1738798.","journal-title":"Oncoimmunology."},{"issue":"7","key":"891_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159397","volume":"11","author":"JL Schehr","year":"2016","unstructured":"Schehr JL, Schultz ZD, Warrick JW, Guckenberger DJ, Pezzi HM, Sperger JM, et al. High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1. PLoS ONE. 2016;11(7): e0159397.","journal-title":"PLoS ONE"},{"issue":"20","key":"891_CR34","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1039\/C7LC00654C","volume":"17","author":"X Jiang","year":"2017","unstructured":"Jiang X, Wong KHK, Khankhel AH, Zeinali M, Reategui E, Phillips MJ, et al. Microfluidic isolation of platelet-covered circulating tumor cells. Lab Chip. 2017;17(20):3498\u2013503.","journal-title":"Lab Chip"},{"issue":"1","key":"891_CR35","doi-asserted-by":"publisher","first-page":"19296","DOI":"10.1038\/s41598-020-76351-4","volume":"10","author":"AB Zaslavsky","year":"2020","unstructured":"Zaslavsky AB, Adams MP, Cao X, Maj T, Choi JE, Stangl-Kremser J, et al. Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. Sci Rep. 2020;10(1):19296.","journal-title":"Sci Rep"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00891-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-022-00891-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00891-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T15:45:29Z","timestamp":1655912729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-022-00891-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1007\/s11523-022-00891-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"7 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RareCyte, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LCK, SK, JL, and ZC have no conflicts of interest to report. ABR, EL, YS, LU, EPK are employees of RareCyte, Inc. LQMC has no direct conflicts of interests but has received minor <i>de minimus<\/i> personal advisory board consulting fees and prior institutional research grant funding from Merck, Pfizer, Dynavax and Novartis, Astra-Zeneca in the last three years, de minimus advisory board consulting fees and current institutional research grant funding from Alkermes. She reports current institutional grant funding only from Oncorus. She reports minor de minimus consulting\/advisory board fees from Cullinan and Elicio, Gilead, Regeneron, Sanofi-Genzyme and Daiichi Sankyo, Ipsen, Nanobiotix, Beigene, Jazz Pharmaceuticals. Research grant funding only provided to her prior institution from Bristol Myers Squibb, Genentech, Seattle Genetics, Lily\/Imclone. Over the last 3 years (all unrelated to this study). PG has received consulting fees from AstraZeneca, Astellas Pharma, Bayer, Bristol Myers Squibb, Dyania Health, EMD Serono, Exelixis, Foundation Medicine, Genentech\/Roche, Genzyme, GlaxoSmithKline,\u00a0Guardant Health, Gilead Sciences, Infinity Pharmaceuticals, Janssen, Lucence Health, Merck, Mirati Therapeutics, Pfizer, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics, Silverback Therapeutics, UroGen, 4D Pharma PLC.\u00a0His\u00a0institution has received grants from Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Merck, Mirati Therapeutics, Pfizer, QED Therapeutics.\u00a0VKG has no direct conflicts of interests with this work but has equity in SEngine Precision Medicine, Novilla, and 3rdEyeBio. VKG is on the scientific boards for Puma Biotechnology, New Equilibrium Biosciences, Phoenix Molecular Designs; he is also on speakers\u2019 bureaus for Puma Biotechnology, Genentech\/Roche, Hologics; and receives research support to his institution from Agendia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing disclosures"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the IRB Committee the Fred Hutchinson Cancer Research Center Cancer Consortium (#10031).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients agreed to participate in this study under informed consent as approved by the Fred Hutchinson Cancer Center Cancer Consortium IRB.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"As part of informed consent for this study, patients agreed to allow the publication of deidentified results.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Deidentified patient data is shared in aggregate within the paper supplement.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"N\/A.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LCK wrote the protocol, consented patients, processed patient samples, performed CTC analysis, performed data analysis, and wrote the manuscript. JL performed biostatistical analysis and wrote the manuscript. SK processed patient samples and performed CTC analysis. ABR performed CTC analysis and wrote the manuscript. EL developed the tissue staining protocol and performed tissue staining and analysis. LU performed CTC analysis. YS contributed to assay development. JL and ZC performed biostatistical analysis and wrote the manuscript. LQC and PG recruited and consented patients and wrote the manuscript. EPK performed tissue staining analysis and wrote the manuscript. VG recruited and consented patients, performed data analysis, and wrote the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}